In-Vitro Diagnostics Detect Cardio-Toxic Biomarkers
At ACC 2010, Siemens Healthcare Diagnostics will highlight new clinical findings that demonstrate the importance and value of cardiac biomarker testing in the treatment and care of cancer patients exposed to potential cardio-toxic effects of chemotherapeutic agents. Cardiac biomarkers, such as troponin I and natriuretic peptides, are well-established for risk stratification of patients with acute coronary syndromes and heart failure. Studies have shown that these biomarkers may also be useful in the early detection of chemo-therapy induced cardio-toxicity.
ACC attendees are invited to visit the Siemens booth to review an educational presentation about cardiac biomarker testing in oncology patients and the future potential for early testing and intervention to help prevent adverse cardiac effects in oncology patients.
The company will explain its comprehensive cardiovascular and oncology product portfolio and the power of collaboration in cardiac care.
More like this
- ASE Study Shows Echocardiography Benefits for Cancer Patients
- ECG Can Detect Early Heart Damage in Cancer Patients
- ASE-EAE Develop Guidelines for Echocardiographic Evaluation of Cancer Patients
- ACC Partners With Diagnostic Company to Develop a Web-Based Biomarker Resource
- Siemens Highlights High Sensitivity C-Reactive Protein Test